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ABSTRACT  
Aim and Objective: The present study is aimed to carry out the effect of the type of GnRH analogue on embryo cleavage. Materials and 
Methods: A total of 403 patients who underwent Intra Cytoplasmic sperm injection were included in the study. They were divided in to 
three groups.  Group I- Embryos which cleaved before 27 hours after injection. Group II- Embryos which cleaved after 27 hours, Group 
III-Embryos which cleaved before and after 27 hours. The effects of GnRh agonist and antagonist on embryo cleavage were compared 
between the three groups. Results: All the 403 patients were analysed. There was no difference in the mean age, duration of ovarian 
stimulation, number of oocytes retrieved, fertilization, cleavage rates and embryo quality between the three groups.  Out of 403 patients, 
early cleavage was observed in 165 patients (40.94 %). Late cleavage was observed in 129 patients (32.01%), both early and late cleavage 
was observed in 109 patients (27.05%). Out of 227 patients in the agonist protocol the early cleavage was observed in 98 patients (43.17%), 
late cleavage was observed in 71 patients (31.28%), and both early and late cleavage was observed in58 patients (25.55%). Out of 176 
patients in the antagonist protocol the early cleavage was observed in 67 patients (38.07%), late cleavage was observed in 58 patients 
(32.95%), and both early and late cleavage was observed in51 patients (28.98%). P 0.563. We observed there was no statistical significant 
difference between agonist and antagonist stimulation protocol on embryo cleavage Conclusion: The embryo cleavage was not affected 
by the type of GnRH analogue used.  
KEYWORDS: Early cleavage, Embryo quality, Intracytoplasmic sperm injection, Ovarian stimulation. 
INTRODUCTION 
In order to decrease multiple pregnancies and attain a maximal 
rate of implantation, selection of the most viable embryo for 
transfer has become a high concern in assisted conception 
treatment. Conventionally, embryo selection is performed by 
using embryo morphology. Other selection methods include 
oocyte and zygote morphology, blastomere symmetry and 
blastocyst culture. In recent times, observation of embryonic 
early cleavage has been highlighted. Numerous studies have 
shown that embryonic early cleavage, which occurs at 25–27 
hours post insemination for in vitro fertilization (IVF) 
/intracytoplasmic sperm injection (ICSI), can be an additional 
marker of viable embryos. Most of these earlier studies were 
only using the gonadotrophin-releasing hormone (GnRH) 
agonist long protocol for pituitary suppression.[1] 
Recently, a GnRH antagonist protocol has become available in 
assisted reproductive treatment. The advantages of GnRH 
antagonist are associated with a lower utilization of 
gonadotropins, a shorter period of stimulation, a lower risk of 
ovarian hyperstimulation syndrome (OHSS), and a lower 
cancellation rate, especially in poor responders. Previous studies 
have shown that using the GnRH antagonist protocol had the 
comparable pregnancy rate when compared with the GnRH long 
agonist protocol. However, some studies have shown that GnRH 
receptors are expressed in human and mouse preimplantation 
ISSN: 2395 - 0471 
Int J Clin and Biomed Res. 2015;1(2): 70-78 Page 70 
 
 
Will the type of GnRH analogue affect the embryo cleavage                                                                                                              Manjula Gopalakrishnan et al. 
embryos, and addition of GnRH antagonist to mouse embryo 
culture media inhibits preimplantation embryo growth. We 
investigated whether the effects of these two different protocols 
upon embryonic development were the same. In the previous 
study, they found that early-cleavage is a reliable predictor for 
embryo implantation.[1] 
In 1980s the GnRH agonist protocol is introduced to suppress 
the release of pituitary follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) by desensitizing the pituitary 
receptors. In late 1990s, the GnRH antagonists have also been 
found effective for ovarian stimulation by directly binding to the 
GnRH receptors, and through which they block GnRH receptor 
activity in a competitive manner and induce an immediate, 
reversible, and quick suppression of gonadotropin release. As a 
result, the GnRH antagonist protocol has also been commonly 
employed recently in the clinical settings with Invitro 
fertilization and embryo transfer treatment. There is evidence 
that application of GnRH antagonist protocol decreases the 
duration of ovulatory stimulus and reduces the occurrences of 
ovarian hyperstimulation syndrome. While these observations 
are exciting and encouraging, controversial results have also 
been reported. [2] 
In recent years, it has become evident that ovarian stimulation, 
although a central factor of IVF, may itself have detrimental 
effects on oogenesis, embryo quality, endometrial receptivity 
and perhaps also perinatal outcomes. [3] 
Therefore, the aim of this study was to investigate the effect of 
the GnRH agonist and GnRH antagonist protocol on the 
embryonic early-cleavage rates. 
MATERIALS AND METHODS 
It was a prospective observational study conducted in the 
Department of Reproductive Medicine, at a tertiary care centre 
from Oct 2010-Jan 2014. A total of 403 patients who underwent 
Intra Cytoplasmic Sperm Injection (ICSI) were included in the 
study in the age group of 21-45 years. Inclusion criteria: All 
patients enrolled for ICSI during this study period were included 
in the study. The patient having only early cleavage embryos, 
the patient having only late cleavage embryos and the patient 
having both early and late cleavge embryos for transfer were 
included in the study. 
Exclusion criteria: Patient age <21 and >45 yrs were excluded 
from the study. 
Short and ultra short protocols for stimulations were excluded 
from the study. 
Embryos beyond Grade III for transfer were excluded from the 
study.  
Informed consent was taken before the enrollment of each 
participant and the Institutional ethical committee approval was 
obtained (IEC/10/JULY/83/29). 
Two stimulation protocols were used in this study.  Patients with 
young age with good ovarian reserve, we used agonist protocol. 
Patients with advanced age, poor ovarian reserve, low 
AntiMulerian Hormone (AMH) level, and PolyCystic Ovarian 
Syndrome(PCOS ) were the indication for the use of antagonist 
protocol. The gonadotropin-releasing hormone (GnRH) agonist 
protocol- A gonodotropin releasing hormone agonist is an 
analogue that activates the receptors resulting in increased 
secretion of Follicle stimulating hormone (FSH), Luteinizing 
hormone (LH). The GnRH antagonist protocol -A 
gonadotropin-releasing hormone antagonist is an analogue that 
blocks the GnRH receptor resulting in an immediate drop in 
gonadotropin (FSH, LH). In the GnRH agonist protocol, 
pituitary down regulation was done with GnRH agonists. Once 
the patient was down regulated completely (had menses, E2 <30 
pg/ml) gonadotropin injections (recombinant follicle 
stimulating hormone/human menopausal gonadotropin) were 
given until the day of hCG administration. The doses were 
adjusted according to the patient's ovarian response. In the 
GnRH antagonist protocol, without down regulation 
gonadotropin injections were administrated daily from the 
second day of the menstrual cycle. The doses were adjusted 
according to the patient's individual ovarian response. Once the 
dominant follicle reached 14 mm in mean diameter, GnRH 
antagonist was administered subcutaneously at a dose of 0.25 
mg daily until the day of hCG administration. In both groups, 
ovulation was induced by the administration of either 
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recombinant h CG or urinary h CG when at least two follicles 
reached 18 mm in diameter, and oocyte retrieval was performed 
34–36 hours later. Oocytes were retrieved transvaginally under 
ultrasound- guidance. Motile sperms were isolated by a swim-
up or gradient centrifugation. Ejaculated, testicular biopsy; 
cryopreserved ejaculated and cryopreserved testicular biopsy 
semen specimens were all included in the study. Intra 
Cytoplasmic Sperm Injection (ICSI) was performed 3–5 h after 
oocyte aspiration with the prepared sperm. Normal fertilization 
was confirmed by the presence of two pronuclei and two polar 
bodies 16–20 h (day1) after Intra Cytoplasmic Sperm Injection 
(ICSI). Normally fertilized oocytes (Zygotes) were spherical 
and had two polar bodies and two PNs. PNs had approximately 
the same size, centrally positioned in the cytoplasm with two 
distinctly clear, visible membranes. The presence of nucleolar 
precursor bodies, their number and size aligned at the PN 
junction were assessed. On the same day, early cleavage 
examination was performed on the zygotes within 27 hours after 
Intra Cytoplasmic Sperm Injection (ICSI). Embryos displaying 
two cells at inspection were designated as 'early cleavage'. The 
embryos that had not yet cleaved to the 2-cell stage after 27 
hours were designated as 'late cleavage'. Two or three embryos 
were transferred on Day2 depending on the patient’s age and 
embryo quality. The embryos that were not transferred were 
cryopreserved. The luteal phase was supported by vaginal 
supplementation of progesterone or intramuscular injection of 
progesterone.  
Pregnancy was determined by a serum β human Chorionic 
Gonodotropin (β h CG) test 14 days post transfer. The clinical 
pregnancy was confirmed by the presence of an intrauterine 
gestational sac with fetal cardiac activity by ultrasound 
examination at 4 weeks after embryo transfer. Patients were 
divided into three groups. Group I- Embryos which cleaved to 
two cells before 27 hours after injection. Group II- Embryos 
which cleaved to two cells after 27 hours. Group III- Embryos 
which cleaved to two cells before and after 27 hours after 
injection. The effects of GnRh agonist and antagonist on embryo 
cleavage were compared between the three groups.   
STATISTICAL ANALYSIS 
The collected data were analysed with SPSS 16.0 version. To 
describe about the data descriptive statistics frequency analysis, 
percentage analysis, means and standard deviation were used. 
For the numerical data nonparametric Mann–Whitney U test 
was used to find the significance. To find the significance in 
categorical data Chi - Square test was used. In all the statistical 
tools, the probability value of p<0.05 was considered as 
significant level. 
RESULTS 
A total of 403 patients were analyzed. The baseline 
characteristics were shown in (Table 1).  
There was no difference in the mean age, duration of ovarian 
stimulation, number of oocytes retrieved, fertilization, cleavage 
rates and embryo quality between the three groups. In our study 
about 67.25 % of the patients were in the age group of 26-35 
years. The type of gonadotrophin used for ovarian stimulation 
was similar in the two groups. Out of 403 patients, early 
cleavage was observed in 165 patients (40.94 %). Late cleavage 
was observed in 129 patients (32.01%), both early and late 
cleavage was observed in 109 patients (27.05%). 
Out of 403 patients 227 patients (56.33%) were given GnRH 
agonist protocol and 176 patients (43.67%) were given 
antagonist protocol. (Table 2) (Figure 1). Out of 227 patients in 
the agonist protocol the early cleavage was observed in 98 
patients (43.17%), late cleavage was observed in 71patients 
(31.28%), and both early and late cleavage was observed in58 
patients (25.55%). Out of 176 patients in the antagonist protocol 
the early cleavage was observed in 67 patients (38.07%), late 
cleavage was observed in 58 patients (32.95%),and both early 
and late cleavage was observed in 51 patients (28.98%).P  
0.563.(Table 3) (Figure 2). 
In this study significantly more MII oocytes in group I than in 
Group II and Group III.    47.02 % MII oocytes in the Group I, 
22.09% MII oocytes in the  Group II, 30.89% MII oocytes in the 
Group III. P 0.051 (Table 4). The results showed that the good 
quality oocytes were 69.27% in the group I, 19.72% in group II 
and 11.01% in group III.P 0.001 which was statistically 
significant (Table 5). But when we compared the good quality 
oocytes in agonist and antagonist there was no significant 
difference. 59.47% vs 47.15% (Table 6). 
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Table 1. Baseline Characteristics 
 
Parameters 
 
Earlycleavage 
Group i  (165) 
 
Latecleavage  
Group ii   (129) 
Earlycleavage 
&latecleavage 
Group iii   (109) 
 
P value 
No of patients 165 129 109 - 
Mean age (yrs) 31 ± 5 31 ± 5 32 ± 5 
0.265 
 
Mean duration of infertility (yrs) 7 ± 4 7 ± 4 8 ± 5 
0.698 
 
No of oocytes retrieved (mean ± SD) 15 ± 8 14 ± 8 15 ± 9 
0.308 
 
No of mii oocytes (mean ± SD) 12 ± 7 10 ± 7 12 ± 7 
0.051 *  
 
No of mi oocytes (mean ± SD) 1 ± 2 1 ± 1 1 ± 1 
0.072 
 
No of gv oocytes (mean ± SD) 1 ± 2 2 ± 3 1 ± 2 
0.505 
 
No of o ocytes  injected (mean ± SD) 12 ± 7 10 ± 6 12 ± 7 
0.028 * 
 
No of o ocytes  fertilized (mean ± SD) 10 ± 6 8 ± 5 9 ± 6 
0.006 ** 
 
No. of grade  i embryos (mean ± SD) 7 ± 5 5 ± 4 7 ± 6 0.005** 
Kruskal-Wallis Test was applied to compare these three groups and get the significance. 
** Highly significant, * Significant.  
Table 2. Protocol and No. of patients 
 
DESCRIPTION 
 
AGONIST  PROTOCOL 
 
ANTAGONIST PROTOCOL 
NO OF PATIENTS        (403) 227   (56.33%) 176    (43.67%) 
 
 
Figure 1: Protocol and No. of patients 
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Table 3.  Effect of protocol and cleavage 
 
PROTOCOL 
 
EARLYCLEAVAGE 
GROUP I (165) 
 
LATECLEAVAGE  
GROUP II (129) 
 
EARLYCLEAVAGE 
&LATECLEAVAGE 
GROUP III (109) 
 
P VALUE 
AGONIST                                 
(227) 
98 (43.17%) 71 (31.28%) 58 (25.55%) 
 
0.563 
 
 
ANTAGONIST                         
(176) 
67 (38.07%) 58 (32.95%) 51 (28.98%) 
When we compared the agonist and antagonist protocol with cleavage of Group I , Group II, and Group III, 
there was no statistical difference between these groups.  p 0.0563. 
 
 
Figure 2: Effect of protocol and cleavage 
Table 4. Comparison of No. of MII oocytes and cleavage  
 
NO OF MII OOCYTES 
 
EARLYCLEAVAGE 
 
GROUP I (165) 
 
LATECLEAVAGE  
   
GROUP II   (129) 
 
EARLYCLEAVAGE 
& LATECLEAVAGE 
GROUP III   (109) 
 
P VALUE 
 
TOTAL NO OF MII OOCYTES 
(4662) 
2192 (47.02%) 1030 (22.09%) 1440 (30.89%) 0.051* 
* Significant  
Table 5.  Effect of oocyte quality and cleavage   
 
OOCYTE QUALITY 
 
EARLYCLEAVAGE 
 
GROUP I (165) 
 
LATECLEAVAGE  
   
GROUP II (129) 
 
EARLYCLEAVAGE 
&LATECLEAVAGE 
GROUP III (109) 
 
P VALUE 
GOOD QUALITY OOCYTES                                      
(218) 
151 (69.27%) 43 (19.72%) 24 (11.01) 
 
0.001** 
 
** Highly significant  
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Table 6. Effect of protocol and oocyte quality 
 
OOCYTE QUALITY 
 
AGONIST  PROTOCOL 
 
 
ANTAGONIST PROTOCOL 
 
GOOD QUALITY  OOCYTES 59.47%    135/227 
47.15%      83/176 
 
Table 7. Effect of embryo grade and cleavage  
 
EMBRYO GRADE 
 
EARLYCLEAVAGE 
 
GROUP I   
 
LATECLEAVAGE  
   
GROUP II    
 
EARLYCLEAVAGE 
&LATECLEAVAGE 
GROUP III    
 
P VALUE 
GRADE  I                                   
 (313) 
158   (50.48%) 75   (23.96%) 80   (25.56%) 
 
0.005** 
 
** Highly significant  
Table 8. Effect of protocol embryo grade 
 
EMBRYO GRADE 
 
AGONIST  PROTOCOL 
 
 
ANTAGONIST PROTOCOL  
 
 TOTAL NO OF GRADE  I    EMBRYOS                               66.09%    (1493/2259) 
 
68.35%   (920/1346) 
 
When we compared the grade I embryos in the three groups 
50.48% in group I , 23.96% in group II, and 25.56 % in group 
III P 0.005, which was also statistically significant (Table 7). 
We analysed for good quality embryos in agonist and antagonist 
protocol there was no difference, 66.09% (1493/2259) vs 
68.35%   (920/1346) (Table 8). 
But we observed the effect of GnRH analogues and early 
cleavage there was no significant difference between agonist 
and antagonist stimulation protocol on early cleavage status 
.43.17%Vs 38.07%. P 0.053 (Table 3). 
DISCUSSION  
The first assisted conception therapies were performed in 
natural unstimulated IVF cycles. Nowadays, gonadotrophins are 
given to induce multiple follicular growth and GnRH analogues 
for the prevention of premature LH surges in IVF.[4] 
The quality of oocytes and developing preembryos is one of the 
most important factors determining the success of an assisted 
reproductive treatment. In order to improve the efficiency of the 
treatment, either more embryos at a time will be transferred or a 
well-recognised stimulation protocol and embryo-selection 
procedure with lower number of transferred embryos is 
practised. There is the need to transfer less but more viable 
embryos to minimise the occurrence of multiple pregnancies. As 
a result of better fertilization and embryo culture techniques, 
patients may produce more good-quality embryos and have 
higher pregnancy and implantation rates.[2] As ovarian 
stimulation protocol is one of the appropriate factors during an 
assisted conception treatment, its embryo quality influencing 
effects are necessary to know. Since 2000 the assessment of 
GnRH agonist vs. GnRH antagonist protocols has been well 
analyzed in clinical studies, most of them focused on the clinical 
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outcome of the two protocols only. But it does not concentrate 
on the on embryo early cleavage.The effects of the GnRH 
analogues on oocyte and embryo-quality and on early cleavage 
development are still not recognised in detail.[5] 
The long agonist protocol for controlled ovarian stimulation is 
generally the most effective and is used most regularly, therefore 
becoming the gold standard. Meta analysis comparison of 
GnRH agonist and antagonist protocol have shown 
comparatively lower pregnancy rate for GnRH antagonist, 
which may have discouraged its acceptance by clinicians.10Since 
the GnRH antagonist protocol is simple, easy, convenient and 
flexible along with the lack of functional ovarian cyst formation 
and “menopausal” symptoms frequently seen in the agonist 
protocol, it has become a better choice by clinical doctors and 
patients. Conversely, data from some randomized clinical trials 
shown that the antagonist protocol retrieves fewere number of 
oocytes along with lower pregnancy rates than the agonist long 
protocol.[2] 
GnRH agonists have been commonly used since the mid-1980 s 
in order to prevent the surge of LH in IVF/ICSI cycles. Since 
their introduction in 1986, the prevalence of severe OHSS has 
been reported to have increased six-fold compared with the 
incidence in IVF cycles stimulated by clomiphene/HMG only. 
In the late 1990s, the GnRH antagonists became available: these 
compounds suppress gonadotrophin release by competitive 
receptor binding resulting in an instant suppression and 
blockage of gonadotrophin secretion rather than pituitary 
desensitization. The safety and efficacy of GnRH antagonists 
and agonists in IVF and ICSI cycles have been reported to be 
same. GnRH antagonists are now part of the therapeutic 
beneficial options of infertility units worldwide.[6]  In our study, 
ovarian stimulation with a GnRH antagonist proved to be more 
commonly successful and with a reduced risk compared with 
cycles using GnRH agonists. The incidence of ovarian hyper 
stimulation syndrome (OHSS) was significantly reduced in the 
GnRH antagonist cycles. 
An initial meta-analysis in the Cochrane database reported that 
GnRH antagonists are associated with a shorter period of 
stimulation, a reduced gonadotropin consumption and a reduced 
ovarian hyperstimulation occurence than long GnRH agonist 
protocols.[7] 
Antagonist appears to be safer due to the lower incidence of 
ovarian hyperstimulation syndrome (OHSS), still, the literature 
has shown that high dose of gonadotropins use with the agonist 
protocol, resulting in higher cost for patients in addition to the 
risk of OHSS.[8] GnRH antagonist protocol produced a similar 
ovarian response, embryo development and pregnancy rates to 
GnRH agonist regime requiring lesser amounts of 
gonadotrophins.[9]  
The resultsfrom our study were similar to these reported studies. 
The results of the current study shown that the GnRH antagonist 
and agonist long protocols provided comparable outcomes. In a 
recent prospective study, there was no significant difference 
between antagonist and agonist groups in terms of pregnancy 
and delivery complications, neonatal outcome and risk of major 
malformations.[10] 
To achieve a singleton pregnancy without minimising the 
implantation rate should be the primary goal in assisted 
reproduction treatment. Till now, embryonic morphology has 
been one of the most useful tools to achieve this goal. In recent 
years, embryonic early-cleavage observed 25–27 hours after 
insemination has been recommeded as another available 
parameter for embryo selection All these previous studies  used 
a GnRH agonist long protocol for pituitary suppression.[1]   
The results of our study showed that, the mean numbers of 
normal fertilized oocytes, good quality oocytes, good embryos 
were all comparable with those in the GnRH agonist group and 
antagonist protocol.  We also observed that embryonic early-
cleavage was a good predictor for early embryonic 
development. In the present study, we found that ther was no 
difference in embryonic early-cleavage rate in using the GnRH 
antagonist protocol and agonist protocol. 
Dynamics of early embryonic development could reflect the 
developmental potential of the embryo. It is identified that early 
cleavage is a strong indicator of the quality and the viability of 
the embryos, although a recent study showed higher 
implantational potential for early-cleavage embryos only with 
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the use of GnRH agonists. We observed significantly higher rate 
of early cleavage in this group did not reach statistical 
significance with the antagonist.[2] In the the previous studies the 
GnRH antagonist may still have some effects on delaying the 
first mitosis of zygotes. [1]     But in the present study, we observed 
that embryonic early cleavage rate was comparable in both  the 
GnRH agonist protocol  and  in the GnRH antagonist  43.17% 
vs 38.07% p 0.563 .In the present study, the results showed that 
the Grade I embryos were significantly higher in the early 
cleavage group. The early cleavage group was comparable in 
both Agonist and antagonist protocol.   
Bidirectional signalling between oocytes and granulose cells is 
necessary for follicular development and the achievement of 
oocyte competence .The nuclear and cytoplasmic maturity of the 
oocyte that accompanies follicular development plays a vital 
role in facilitating fertilisation and the early stages of embryonic 
development. When the developing oocytes are exposed to 
supraphysiological concentrations of gonadotrophins may 
disturb oocyte maturation and the completion of meiosis leading 
to chromosomal aneuploid oocytes and/or embryos.  Therefore, 
the gonadotrophin stimulation compromised not only uterine 
receptivity but also oocyte/embryo developmental competence. 
So, milder ovarian stimulation protocol seem to be less 
detrimental to the vulnerable process of nuclear maturation and 
chromosomal segregation. [3] 
CONCLUSION 
In conclusion, the results of this study showed that the early-
cleavage rate was comparable in both the GnRH antagonist 
protocol and in the GnRH long agonist protocol.  The results 
also showed that early cleavage of zygote seems to be a 
powerful predictor for embryo implantation potential when both 
the GnRH antagonist protocol and GnRH agonist protocol was 
applied. There was no significant effect of GnRH antagonist 
protocol and GnRH agonist protocol on embryo cleavage. 
Moreover, GnRH antagonist protocol required a shorter 
stimulation period plus fewer side effects. Hence GnRH 
antagonist protocol provided means for a friendlier, convenient 
and cost effective protocol for patients and it can be used in 
routine assisted reproductive technology treatment. 
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